Table 1. PD-1/PD-L1 inhibitors with labeled indication for non-small cell lung cancer (NSCLC).

Drug	Labeled indication	Mechanism of action
Pembrolizumab	• Single agent in stage III NSCLC (who are not candidates for surgical resection or definitive chemoradiation) or in patients with metastatic NSCLC with PDL-1 TPS ≥1% with no EGFR or ALK genomic aberrations	Anti-PD-1 humanized monoclonal antibody which inhibits PD-1 by binding the PD-1 receptor on T-cells, blocking PD-L1 and PD-L2 from binding
	• Combination with pemetrexed and platinum chemotherapy for metastatic non-squamous NSCLC with no EGFR or ALK genomic aberrations
	• Combination with carboplatin and either paclitaxel or paclitaxel (protein bound) metastatic squamous SCC
Nivolumab	• Treatment of metastatic non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy	Anti-PD-1 humanized monoclonal antibody which inhibits PD-1 by binding the PD-1 receptor on T-cells, blocking PD-L1 and PD-L2 from binding
	• Patients with EGFR or ALK genomic tumor aberrations should have disease progression (on approved EGFR- or ALK-directed therapy) prior to receiving Nivolumab
Durvalumab	• Treatment of unresectable stage III non-small cell lung cancer which has not progressed following concurrent platinum-based chemotherapy and radiation therapy	Human immunoglobulin G1 kappa monoclonal antibody which blocks programmed PD-L1 from binding to PD-1 and CD80
Atezolizumab	• In combination with bevacizumab, paclitaxel, and carboplatin for metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumor aberrations	Humanized monoclonal antibody immune checkpoint inhibitor that binds to PD-L1 to selectively prevent the interaction between PD-1 CD80
	• In combination with paclitaxel [protein bound] and carboplatin for metastatic NSCLC in patients with no EGFR or ALK genomic tumor aberrations